Bio-Rad Laboratories

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.

Curiosity Diagnostics is a pre-commercial platform company focused on developing point-of-care systems for digital PCR analyses. Their flagship product, PCR|ONE, is a versatile platform that enables the creation of tailored and cost-effective diagnostic panels for various pathogens, including MRSA and SARS-CoV-2. This innovative technology allows for rapid expansion and adaptation of assay panels, addressing evolving public health needs and epidemiological threats efficiently.

Dropworks, Inc., located in Phoenix, Arizona, specializes in advanced digital PCR technology known as FluxPCR, which significantly enhances the quantification of DNA and RNA in both research and clinical environments. The company employs innovative continuous flow droplet nanoreactors to streamline workflows, achieving high throughput and low costs while providing absolute quantification with ultra-high sensitivity. This technology allows for rapid assay mixing and delivers results in under 30 minutes, making it suitable for urgent diagnostic applications, including personalized medicine and cancer genotyping. Dropworks' integrated microfluidic solutions also enable the portability of digital PCR, allowing users to conduct molecular biology analyses in various settings, thus facilitating more accurate data collection and efficient treatment processes in areas such as cancer screening and viral load quantification.

Celsee Diagnostics (formerly DeNovo Sciences) mission is to provide an easy to use platform for cancer research and diagnosis. Specifically, the company will sell an instrument system and reagent kit that allows for the separation, detection, and retrieval of circulating tumor cells (CTCs) from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. Their company is developing a proprietary product that will not only allow researchers to identify and capture rare and difficult to harvest cancer cells in a microfluidic chip but also enable them to conduct downstream molecular analysis. This technology allows for the development of personalized therapies as well as the ability to monitor patient prognosis.

RainDance Technologies, based in Billerica, Massachusetts, specializes in developing genomic tools for non-invasive liquid biopsy applications focused on the research, early detection, and treatment of cancer, as well as other inherited and infectious diseases. The company offers a range of innovative products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for multiplex detection of various genetic materials. Additionally, RainDance provides the ThunderStorm automated next-generation sequencing content enrichment solution, and the ThunderBolts NGS panels, designed for profiling significant cancer mutations and targeting genes associated with myeloid disorders. Through its advanced droplet technology, RainDance enables research institutions and laboratories to conduct precise genetic analysis, facilitating the understanding of complex genetic variations. Founded in 2004, the company operates as a subsidiary of Bio-Rad Laboratories and serves a global market through sales representatives and distributors.

Oxford Impedance Diagnostics Limited is a company that specializes in the research, design, and marketing of diagnostic tests aimed at measuring clinical biomarkers. Founded in 2016 and based in Oxford, United Kingdom, the company focuses on providing solutions that facilitate personalized medicine, enhance early risk detection, and support disease diagnosis and management. Its innovative products are intended to reduce healthcare costs while improving patient outcomes, contributing to more effective healthcare practices.

GnuBIO specializes in the development of scalable DNA sequencing technology aimed at the diagnostic and applied markets. The company employs an emulsion-based microfluidic approach to create a comprehensive desktop sequencing system, enabling the analysis of single genes, gene panels, and whole genomes. GnuBIO's proprietary platform integrates all necessary steps for DNA sequencing—including target selection, enrichment, amplification, sequencing, and analysis—into a single interface and process. This innovative system significantly accelerates result delivery, shortening the time required from days to just hours, thus enhancing the efficiency of both research and clinical laboratory workflows.

For 30 years, AbD Serotec has been one of the world leaders in antibody production, supplying thousands of catalog antibodies, kits and accessories to scientific researchers requiring products from dendritic cell antibodies through to antibodies for microbiology. We pride ourselves on providing great customer support for all our products and services and have reliable staff on site to help with any of your antibody needs. Where are we? AbD Serotec has an ISO 9001 certified antibody production facility in Kidlington, near Oxford, UK. This facility is AbD Serotec's global headquarters, and supports our other center in Raleigh, North Carolina, USA. Our ISO 9001 certified laboratories in Puchheim, near Munich in Germany are home to our unique HuCAL custom monoclonal generation services. What can we provide for you? With antibody specialists in a range of scientific fields, AbD Serotec is able to produce and supply high quality antibodies straight to you, tailored for use with various applications including western blotting and flow cytometry. With an extensive collection of primary antibodies for studying innate immunity and having the largest range of veterinary antibodies and reagents, we empower scientists to make rewarding new discoveries. Can’t find what you need? Look no further than our custom antibody services; antibodies tailored to your needs with a wide range of antibody production and modification options. Our unique HuCAL service gives you the cutting edge of monoclonal antibody generation. A new chapter with Bio-Rad In January 2013, AbD Serotec became part of Bio-Rad Laboratories, Inc. Bio-Rad has played a leading role in the progression of scientific discovery for 60 years by providing a broad range of tools and services to the life science research and clinical diagnostics markets. With more than 7,100 employees globally, Bio-Rad are able to serve more than 100,000 research and industry customers worldwide. For more information, visit bio-rad.com. Our Mission Through innovation, 30 years of industry knowledge, and understanding our customers changing needs we will continue to build strong customer relationships and aid in advancing scientific research.

Propel Labs - Cell Sorting System Division is a automated, easy-to-use benchtop sorting flow cytometer.

QuantaLife, Inc. is a biotechnology startup focused on developing and marketing innovative nucleic acid testing technologies for various sectors, including life science research, clinical diagnostics, and personalized medicine. The company offers advanced genetic analysis platforms designed to facilitate rapid detection and quantification of nucleic acids in complex samples using a flexible, automated instrument. QuantaLife's proprietary testing method significantly enhances performance compared to existing technologies while reducing costs, making it a valuable tool for researchers and clinicians. By providing a cost-effective and high-resolution platform for validating next-generation sequencing discoveries, QuantaLife enables the exploration of complex genetic landscapes, the identification of new disease associations, and the advancement of molecular diagnostic tests.

Biotest - Businesses provides pharmaceutical, biotherapeutic, and diagnostic products.

DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening.

Blackhawk is a manufacturer of quality control products for use in laboratories that perform infectious disease testing procedures.

Ciphergen Biosystems, Inc. is focused on the discovery, development and commercialization of high-value, molecular diagnostic products to improve patient care. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs primarily in oncology with an initial focus in ovarian and prostate cancer. Based in Fremont, California

Ciphergen Biosystems - ProteinChip Systems Business is a Enhanced Laser Desorption/ Ionization.

MJ Research, Inc. is a biotechnology company specializing in premium instruments and consumables used in modern biological research. MJ Research pioneered the use of Peltier-effect technology and has introduced a number of other innovations in the thermal-cycling field. MJ Research employs approximately 300 employees.

Quantase Ltd. is a company specializing in newborn screening diagnostic products.

Helix Diagnostics is specializing in the development and manufacture of test kits for autoimmune disease.

Bio-Rad Pasteur is a manufacturer and distributor of life science research and clinical diagnostics products. Bio-Rad Pasteur was formerly known as Pasteur Sanofi-Diagnostics.